Update of TRUCE-02: An Open Label, Single-arm, Phase 2 Study of Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma (HR-NMIBC) Which is Not Completely Resectable.
Nab-Paclitaxel;Tilelizumab
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Update of TRUCE-02: An Open Label, Single-arm, Phase 2 Study of Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma (HR-NMIBC) Which is Not Completely Resectable. ### Output: Nab-Paclitaxel;Tilelizumab